Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial

Brown, W. Virgil; Bays, Harold; Hassman, David; McKenney, James M.; Chitra, Rohini; Hutchinson, Howard G.; Miller, Elinor

doi:10.1067/mhj.2002.129312

Cited by 151 publications

(121 citation statements)

References 18 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…90 (For further details of these studies, see Appendix 12. ) A further two studies of 6 months or longer were identified which compared the LDL-C-lowering efficacy of rosuvastatin (5 and 10 mg) with that of atorvastatin in patients with hypercholesterolaemia in northern Europe (study 4522IL/0026 125 ) and with that of pravastatin or simvastatin in similar patients in the USA (study 4522IL/0028 126 ). These studies did not report clinical outcomes.…”

Section: Direct Statin-statin Comparisonsmentioning

confidence: 99%

A systematic review and economic evaluation of statins for the prevention of coronary events

Ward

Jones²,

Pandor³

et al. 2007

Health Technol Assess

346

312

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as r...

show abstract

Section: Direct Statin-statin Comparisonsmentioning

confidence: 99%

A systematic review and economic evaluation of statins for the prevention of coronary events

Ward

Jones²,

Pandor³

et al. 2007

Health Technol Assess

346

312

View full text Add to dashboard Cite

show abstract

“…Myopathy and hepatic damage are the two major but uncommon adverse events 8,9) . Acute pharmacokinetic studies have shown that Asians may have higher blood levels of rosuvastatin than Caucasians but whether this results in more adverse events has not been demonstrated…”

mentioning

confidence: 99%

Effects of Rosuvastatin on Low-Density Lipoprotein Cholesterol and Plasma Lipids in Asian Patients with Hypercholesterolemia

Tan

Low

Lim

et al. 2009

JAT

View full text Add to dashboard Cite

Aims:Rosuvastatin is more efficacious than other statins in lowering low-density lipoprotein cholesterol (LDL-C). Studies showing higher blood levels in Asians have resulted in concerns regarding increased adverse drug reactions. This study aimed to evaluate the efficacy and safety of rosuvastatin in hypercholesterolemic Asian patients. Methods: This retrospective observational study was conducted on statin-naive patients and statinswitch patients. Patients were treated with rosuvastatin for ≥ 8 weeks. Primary outcomes were changes in LDL-C levels and proportions of patients achieving their goals (primary prevention, LDL-C ≤ 130 mg/dL; secondary prevention, LDL-C ≤ 100 mg/dL). Results: Of 1007 hypercholesterolemic patients, 483 were statin-naive (LDL-C 161 40.8 mg/dL) and 524 were statin-switch patients (LDL-C 132.7 36.9 mg/dL). In statin-naive patients, rosuvastatin significantly reduced LDL-C, total cholesterol, and triglycerides by 39.9%, 28.8%, and 9.2%, respectively (p 0.001). Eighty-one percent of these patients achieved LDL-C goals. In the statinswitch cohort, LDL-C, total cholesterol, and triglycerides levels were significantly reduced by 24.5%, 16.6%, and 3.8%, respectively (p 0.001). Achievement of target LDL-C levels increased from 29% to 72.9%. There was no significant adverse drug reaction. Conclusion

show abstract

“…It has been suggested that the LDL-C lowering effect of statins could be more prominent in Asians than in Caucasians, and that a relatively low-dose statin could be used to manage dyslipidemia in Korean patients with low-to-moderate risks [11,14]. The reported LDL-C level reduction rates in representative Caucasian studies were −35.7%±7.1% [3], −42.6%± 10.5% [4], −39.1%±9.0% [5], −52.1%±7.5% [4], −37.9%± 14.0% [6], and −26.0%±8.8% [7] for atorvastatin 10, 20 mg, rosuvastatin 5, 10 mg, pitavastatin 2 mg, and pravastatin 40 mg, respectively. A meta-analysis of randomized, double-blind statin trials showed similar findings with regard to the LDL-C level reduction rates such as 36.8% in patients treated with 10 mg of atorvastatin, 29.7% in patients treated with 40 mg of pravastatin, and 45.8% in patients treated with 10 mg of rosuvastatin [17].…”

Section: Discussionmentioning

confidence: 97%

“…However, the 2013 American College of Cardiology/American Heart Association (ACC/ AHA) guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults did not recommend specific treatment targets since most of the trials regarding statins and cardiovascular outcomes did not test for specific LDL-C goals [2]. In addition, ACC/AHA recommended a specific dose of statin based on lipid-lowering efficacy [2] from previous clinical trials [3][4][5][6][7]. In contrast, the current treatment guidelines for dyslipidemia recommended by the Korean Society of Lipidology and Atherosclerosis, the Korean Academy of Medical Sciences, or the Korean Diabetes Association, provide actual LDL-C target levels [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus

2017

View full text Add to dashboard Cite

Background: There has been evidences of ethnic differences in the low density lipoprotein cholesterol (LDL-C) lowering effect of statin. We aimed to evaluate the efficacy of moderate-intensity statins in the treatment of dyslipidemia among Korean patients with type 2 diabetes mellitus (T2DM). Methods: We analyzed a retrospective cohort that consisted of Korean patients with T2DM aged 40 to 75 years who had been prescribed any of the moderate-intensity statins (atorvastatin 10 or 20 mg, rosuvastatin 5 or 10 mg, pitavastatin 2 mg, or pravastatin 40 mg). Among them, only patients with baseline lipid profiles before starting statin treatment were selected, and changes in their lipid profiles before and 6 months after statin therapy were analyzed. Results: Following the first 6 months of therapy, the overall LDL-C reduction was −47.4% (interquartile range, −56.6% to −34.1%). In total, 92.1% of the participants achieved an LDL-C level of <100 mg/dL, 38.3% had a 30% to 50% reduction in their LDL-C levels, and 42.3% had a reduction in their LDL-C levels greater than 50%. The response rates of each drug for achieving a LDL-C level <100 mg/dL were 81.7%, 93.1%, 95.0%, 95.0%, 96.5%, and 91.7% for treatment with atorvastatin doses of 10 or 20 mg, rosuvastatin 5 or 10 mg, pitavastatin 2 mg, and pravastatin 40 mg, respectively. Conclusion: In conclusion, the use of moderate-intensity statins reduced LDL-C levels less than 100 mg/dL in most of the Korean patients studied with T2DM. The efficacies of those statins were higher than expected in about 42% of Korean patients with T2DM.

show abstract

Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial

Cited by 151 publications

References 18 publications

A systematic review and economic evaluation of statins for the prevention of coronary events

A systematic review and economic evaluation of statins for the prevention of coronary events

Effects of Rosuvastatin on Low-Density Lipoprotein Cholesterol and Plasma Lipids in Asian Patients with Hypercholesterolemia

Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus

Contact Info

Product

Resources

About